Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Marc Bonaca to Heart Failure

This is a "connection" page, showing publications Marc Bonaca has written about Heart Failure.

 
Connection Strength
  
 
 
3.048
  
  1. Canonico ME, Hsia J, Chiu ST, Tseng PK, Mudd JO, Remick JD, Patel B, Chuang YH, Gluckman TJ, Bonaca MP. Temporal shift in prevalence of heart failure diagnoses and comorbidities within 2 US integrated health systems. Am J Manag Care. 2025 Aug 01; 31(8):e238-e240.
    View in: PubMed
    Score: 0.350
  2. Gluckman TJ, Chiu ST, Rider D, Tseng PK, Mudd JO, Remick JD, Granowitz C, Carroll A, Sikirica S, Canonico ME, Hsia J, Bonaca MP. Relationship Between Left Ventricular Ejection Fraction and ICD-10 Codes Among Patients Hospitalized With Heart Failure. Clin Cardiol. 2024 12; 47(12):e70055.
    View in: PubMed
    Score: 0.334
  3. Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial. Clin Cardiol. 2023 03; 46(3):348-349.
    View in: PubMed
    Score: 0.294
  4. Canonico ME, Hsia J, Cannon CP, Bonaca MP. Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney Disease. JACC Heart Fail. 2022 12; 10(12):989-991.
    View in: PubMed
    Score: 0.290
  5. Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Clin Cardiol. 2022 Aug; 45(8):831-838.
    View in: PubMed
    Score: 0.284
  6. Martins EB, Madrini V, Ramos Souza PV, Tavares CAM, Albuquerque MT, Santo KE, Harrington JA, Canonico ME, El Rafei A, Bonaca MP, Guimaraes PO. ANSWER-HF: sacubitril-valsartan reduces NT-proBNP in heart failure due to Chagas cardiomyopathy despite no reverse remodeling. Heart Fail Rev. 2026 03 23; 31(1).
    View in: PubMed
    Score: 0.091
  7. Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J. 2026 Feb 11; 47(6):683-697.
    View in: PubMed
    Score: 0.091
  8. Mentz RJ, Butler J, McMullan CJ, Wojdyla DM, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Zannad F. Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial. Eur J Heart Fail. 2025 Dec; 27(12):2825-2836.
    View in: PubMed
    Score: 0.088
  9. Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, Zieroth SR, Bonaca MP, Sauer AJ. Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, Evidence, and Unanswered Questions. JACC Heart Fail. 2025 Oct; 13(10):102637.
    View in: PubMed
    Score: 0.088
  10. Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025 Sep 27; 406(10510):1351-1362.
    View in: PubMed
    Score: 0.088
  11. Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Felker GM, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, She L, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025 Sep 27; 406(10510):1341-1350.
    View in: PubMed
    Score: 0.088
  12. Haller PM, Melloni GEM, Berg DD, Kamanu FK, Lai YP, Antman EM, Bhatt DL, Bonaca MP, Cannon CP, Giugliano RP, O'Donoghue ML, Scirica BM, Wiviott SD, Chasman D, Everett BM, Braunwald E, Morrow DA, Ridker PM, Ellinor PT, Sabatine MS, Ruff CT, Marston NA. A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. J Am Coll Cardiol. 2025 Sep 23; 86(12):860-873.
    View in: PubMed
    Score: 0.088
  13. Zannad F, Reddy YNV, Barash I, Anstrom KJ, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor CM, Ponikowski P, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Butler J. Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR. J Am Coll Cardiol. 2025 Dec 16; 86(24):2471-2491.
    View in: PubMed
    Score: 0.088
  14. Rafei AE, Harrington JA, Tavares CAM, Guimarães PO, Ambrosy AP, Bonaca MP, Sauer AJ, Vardeny O, Canonico ME. Heart failure with preserved ejection fraction therapeutics: in search of the pillars. Heart Fail Rev. 2025 09; 30(5):1005-1014.
    View in: PubMed
    Score: 0.086
  15. Saldarriaga CI, Zannad F, McMullan CJ, Xing A, Gates D, Anstrom KJ, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Reddy YNV, Rosano GMC, Senni M, Udelson J, Voors AA, Butler J. Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial. Eur J Heart Fail. 2025 Aug; 27(8):1426-1435.
    View in: PubMed
    Score: 0.085
  16. Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial. Eur J Heart Fail. 2025 Feb; 27(2):209-218.
    View in: PubMed
    Score: 0.083
  17. Verma S, Dhingra NK, Bonaca MP, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Iwata T, Nordaby M, Brueckmann M, Pocock SJ, Packer M. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled. Arterioscler Thromb Vasc Biol. 2023 07; 43(7):1334-1337.
    View in: PubMed
    Score: 0.075
  18. Kato ET, Morrow DA, Guo J, Berg DD, Blazing MA, Bohula EA, Bonaca MP, Cannon CP, de Lemos JA, Giugliano RP, Jarolim P, Kempf T, Kristin Newby L, O'Donoghue ML, Pfeffer MA, Rifai N, Wiviott SD, Wollert KC, Braunwald E, Sabatine MS. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J. 2023 01 21; 44(4):293-300.
    View in: PubMed
    Score: 0.073
  19. Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, Freitas C, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022 11; 24(11):2029-2036.
    View in: PubMed
    Score: 0.073
  20. Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DA. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. J Am Heart Assoc. 2021 05 04; 10(9):e018673.
    View in: PubMed
    Score: 0.065
  21. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 05 28; 139(22):2528-2536.
    View in: PubMed
    Score: 0.056
  22. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 05 28; 139(22):2516-2527.
    View in: PubMed
    Score: 0.056
  23. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 06; 200:83-89.
    View in: PubMed
    Score: 0.052
  24. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10.
    View in: PubMed
    Score: 0.031
  25. Zelniker TA, Jarolim P, Silverman MG, Bohula EA, Park JG, Bonaca MP, Scirica BM, Morrow DA. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS. Clin Chem Lab Med. 2019 06 26; 57(7):1084-1092.
    View in: PubMed
    Score: 0.014
  26. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 01 24; 380(4):347-357.
    View in: PubMed
    Score: 0.014
  27. Mok Y, Ballew SH, Bash LD, Bhatt DL, Boden WE, Bonaca MP, Carrero JJ, Coresh J, D'Agostino RB, Elley CR, Fowkes FGR, Jee SH, Kovesdy CP, Mahaffey KW, Nadkarni G, Peterson ED, Sang Y, Matsushita K. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. J Am Heart Assoc. 2018 07 07; 7(14).
    View in: PubMed
    Score: 0.013
  28. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012 Jan; 58(1):257-66.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)